RoboSense Reports 2026 Interim Results, with Robotics LiDAR Sales Volume Up 510.4% Year over Year

RoboSense reported H1 2026 revenue of RMB 1.02B (+30.2% YoY) led by LiDAR shipments of 719,200 units (+169.6% YoY), including robotics LiDAR volume of 282,600 units (+510.4% YoY). The company also launched full-scale volume production and customer delivery of its E2 mass-production LiDAR model using the Peacock chipset, and it plans first commercial deliveries of new robotics “eyes” (Space Camera) starting by end-Q3 2026, with “skin” and “muscles” deliveries by end-Q3/Q4 2026. Management frames 2026 as a commercialization inflection point as the portfolio expands beyond LiDAR into robotics components, supporting growth and profitability into 2027.

Analysis

The investable question is not whether unit growth is strong; it is whether RoboSense can convert from a cyclical sensor vendor into an embedded robotics platform with repeatable attach revenue. If the new “eyes/skin/muscles” stack gets designed into third-party robots, the market can justify a higher multiple than a pure LiDAR name because switching costs rise and the revenue base broadens beyond one product cycle. But that re-rating only works if these new lines scale with acceptable gross margin and do not become custom, low-visibility programs that inflate top-line growth while compressing cash conversion.

Second-order winners are robot OEMs and integrators that can outsource perception and actuation rather than build internally; that should lower time-to-market and favor scale players in Chinese embodied AI. The losers are smaller sensor startups and pure-play LiDAR comps such as HSAI, OUST, and INVZ, which now face a more integrated competitor that can bundle perception, tactile sensing, and joint modules. The risk is that the market extrapolates prototype wins into durable BOM share too quickly; if RoboSense needs heavy customer-specific customization, the apparent diversification could actually worsen working capital and extend payback.

Near term, the catalyst path is Q3/Q4 delivery evidence, not the press-release language. The stock can trade well for days to weeks on platform narrative alone, but the 1-3 month test is whether management shows confirmed SOPs, repeat orders, and no margin deterioration from the new product ramp. The contrarian view is that the move may be underdone if investors still anchor on LiDAR; but it is more likely overdone if they are already paying for a 2027 robotics-platform story without proof of operating leverage. Falsifiers: delayed customer acceptance, lower-than-expected gross margin, or inventory growth outrunning cash generation.

Key Decisions for Investors

• Long MTAKU / 2498.HK on weakness versus short HSAI for a 1-3 month relative-value trade; the thesis is platform diversification versus pure-play LiDAR commoditization. Exit if RoboSense fails to confirm Q3 customer deliveries or if HSAI re-accelerates booking growth.
• If options are liquid, buy a 3-6 month call spread on MTAKU/2498.HK rather than outright stock to capture narrative re-rating while limiting downside from commercialization delays.
• Set an alert on MTAKU/2498.HK gross margin and operating cash flow at the next update; if new robotics categories dilute margin or inventory rises faster than revenue, treat the platform story as unproven and fade rallies.
• Watch HSAI, OUST, and INVZ for valuation compression after this print; use any sector-strength bounce to initiate small shorts or reduce longs if the market starts paying up for integrated robotics stacks over standalone LiDAR.
• No aggressive long if 2027 guidance is still qualitative; wait for evidence of repeat enterprise orders and SOP conversion before adding size. The falsifier is a revenue beat without cash-flow conversion.